Lymphoma & Plasma Cell Disorders
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
Conference Coverage
Study halted; ‘hyperprogression’ seen with nivolumab for R/R PTCL
ORLANDO –
Conference Coverage
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL
The use of a nurse navigation program to facilitate care helped iron out racial disparities that could lead to poor outcomes.
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
News
Early lenalidomide may delay progression of smoldering myeloma
Researchers said the findings from the phase 3 study support early treatment as the new standard of care in patients with high-risk smoldering...
News
CAR T-cell ‘cocktail’ may overcome antigen escape relapse
The pilot study used a sequential infusion of a third-generation chimeric antigen receptor T-cell “cocktail” targeting CD19 and CD22.
